1:18AM POZEN presents data showing PA32540 provides faster gastric acid reduction than enteric-coated Omeprazole (POZN) 6.49 : Co presentes data from a Phase 1 study that found that the investigational compound, PA32540, provides faster protection compared with delayed-release, enteric-coated omeprazole, as measured by mean time to gastric pH. The Key Findings include: Mean time to first gastric pH >4 was significantly faster with PA32540 compared to the enteric-coated aspirin + enteric-coated omeprazole group; The percent time gastric pH >4 was 50.6% for PA32540 and 57.6 for enteric-coated aspirin + enteric-coated omeprazole group; The relative bioavailability of omeprazole following seven daily doses with PA32540 was 43% lower than that from enteric-coated omeprazole 40 mg.
Market Data 
Markets 
AI
